The ubiquitin-proteasome pathway is critically involved in the pathology of neurodegenerative diseases characterized by protein misfolding and aggregation. Data in the present study suggest that the polyglutamine neurodegenerative disease protein, ataxin-3 (AT3), functions in the ubiquitin-proteasome pathway. AT3 contains an ubiquitin interaction motif (UIM) domain that binds polyubiquitylated proteins with a strong preference for chains containing four or more ubiquitins. Mutating the conserved leucine in the first UIM (L229A) almost totally eliminates binding to po lyubiquitin chains while a similar mutation in the second UIM (L249A) also inhibits binding to polyubiquitin chains but to a lesser extent. Both wild-type and pathological AT3 increase cellular levels of a short-lived GFP that is degraded by the ubiquitin-proteasome pathway. AT3 has several properties characteristic of ubiquitin proteases including decreasing polyubiquitylation of 125 I-lysozyme by removing ubiquitin from polyubiquitin chains, cleaving a ubiquitin protease substrate, and binding the specific ubiquitin protease inhibitor, ubiquitinaldehyde. Mutating the predicted catalytic cysteine in AT3 inhibits each of these ubiquitin protease activities. The ability to bind and cleave ubiquitylated proteins is consistent with AT3 playing a role in the ubiquitin-proteasome system. This raises the possibility that pathological AT3, which tends to misfold and aggregate, may be exposed to aggregate-prone misfolded/denatured proteins as part of its normal function.
Introduction
Spinocerebellar ataxia type-3 (SCA3) is the most common dominantly inherited cerebellar ataxia and a member of the polyglutamine neurodegenerative disease family (1) (2) (3) (4) . As is the case with other members of this family, the protein mutated in SCA3, ataxin-3 (AT3), causes pathology through an apparent gain of function associated with expansion of a CAG repeat that codes for a polyglutamine domain within the protein. Other diseases in this family include Huntington's, dentatorubral pallidoluysian atrophy, spinal and bulbar muscular atrophy, and SCA1, 2, 6, and 7.
A prominent feature in these diseases is the presence of nuclear, and in some cases cytoplasmic inclusions of aggregated pathological protein (5) (6) (7) (8) . Typically, inclusions are highly ubiquitylated and in many cases proteasomes are associated with inclusions which suggests an attempt to degrade the aggregated proteins (5,6,9 -11).
Targeting a protein for proteasome degradation is a multi-step iterative process involving an E1 activating enzyme, E2 ubiquitin carrier/conjugating enzymes, and E3 ubiquitin ligases which generate polyubiquitin chains linked to the ε-amino group of lysine(s) in the protein targeted for degradation (12) . Editing and disassembly of polyubiquitin chains as well as recycling ubiquitin is critical for cellular homeostasis. These functions are carried out by cysteine proteases known as deubiquitinating enzymes (DUBs; 13, 14) . The two major families of DUBs are ubiquitin Cterminal hydrolases (UCHs) and ubiquitin specific proteases (USPs). UCHs are well-conserved proteases that prefer cleaving small leaving groups from the C-terminus of ubiquitin and primarily function in maintaining high levels of free ubiquitin in cells. USPs are a large highly divergent family of proteases with substrate specificities ranging from very general deubiquitinating properties to highly specific cleavage of ubiquitin from a single or small 4 number of protein targets; USPs primarily function in ubiquitin chain editing and disassembly (13, 14) .
DUBs as well as other regulators of the ubiquitin proteasome pathway (UPP) have been linked to neurodegenerative diseases that are characterized by protein misfolding and aggregation. In some cases mutations or polymorphisms in regulators of the UPP are responsible for inherited forms of the disease or modulate the disease phenotype. For instance, mutation of Parkin, an E3 ubiquitin ligase, results in early onset Parkinson's disease, and a polymorphism resulting in reduced ligase activity of the bifunctional DUB, UCH-L1 (15) , is associated with decreased susceptibility to Parkinson's disease (16, 17) . This same polymorphism in UCH-L1 has also been linked to the age of onset in Huntington's disease (18) . Mutations in UCH-L3, as well as mutations in ubiquitin and ubiquitin ligases enhance degeneration in a Drosophila model of SCA1 (19) . These and other studies support the hypothesis that the UPP is intimately linked to neurodegenerative diseases characterized by protein misfolding and aggregation (20, 21) .
Although misfolded polyglutamine proteins may be exposed to the UPP as part of normal protein turnover there is little data to suggest that polyglutamine proteins are exposed to the UPP as part of their normal cellular functions. If a polyglutamine protein were part of this pathway it would create a particularly dangerous situation in which the pathological protein with its destab ilizing expanded polyglutamine domain (22) and tendency to aggregate (23,24) is exposed to misfolded proteins which could increase the probability of protein aggregation.
Based on its sequence, AT3 may function in the UPP. Depending on the splice variant, AT3 has either 2 or 3 potential ubiquitin interaction motifs (UIMs; 25) that have recently been shown to 5 bind mono and/or polyubiquitylated proteins (26, 27) . During the course of our studies to determine if AT3 binds ubiquitylated species, we found that AT3 not only binds polyubiquitylated chains and proteins but it also exhibits ubiquitin protease activity that is inhibited by mutating the predicted active site cysteine.
Results

AT3 binds ubiquitin chains containing four or more ubiquitins through its UIM domain
The ubiquitin interaction motif (UIM) is a recently identified protein motif that binds mono and/or polyubiquitylated proteins (25) (26) (27) . The major splice form of AT3 has two predicted UIMs located between its conserved N terminus and the polyglutamine domain (Fig. 1A) . To determine if AT3 binds ubiquitylated proteins, cell lysates were incubated with MBP-AT3 and associated proteins pulled down with amylose beads. Both wild-type and pathological AT3 bind ubiquitylated cellular proteins equally whereas MBP does not bind ubiquitylated proteins (Fig.   1B ). Monoubiquitylated as well as polyubiquitylated proteins are present in cell lysates; therefore, the preference of AT3 for ubiquitylated species was determined by the ability of AT3 to bind free ubiquitin, a monoubiquitin fusion protein, or polyubiquitin chains of varying lengths.
Under assay conditions used, AT3 does not bind free ubiquitin, a monoubiquitin fusion protein or ubiquitin chains containing less than 4 ubiquitins (Fig. 1C) . However, AT3 binds polyubiquitin chains containing 4 or more ubiquitins which is the chain length required to target protein substrates to the proteasome (28) . No obvious difference in binding between wild -type and pathological AT3 was observed in these experiments.
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Polyubiquitin chains were used to identify the domain of AT3 responsible for binding polyubiquitylated proteins. Full length AT3, AT3(1-291), and AT3 (191-291) containing the UIMs bind ubiquitin chains whereas AT3 or the polyglutamine containing C-terminus (C-29Q) do not (Fig. 1D) . Mutating the conserved leucine in the first UIM (L229A) almost totally eliminates binding to polyubiquitin chains while a similar mutation in the second UIM (L249A) inhibits binding to polyubiquitin chains but to a lesser extent (Fig. 1E ). Together these data indicate that the UIMs are responsible for AT3 binding to polyubiquitylated species containing chains of 4 or more ubiquitins.
AT3 increases levels of short-lived GFP-u
GFP-u is a short-lived GFP containing a destabilizing sequence that targets it for degradation by the ubiquitin proteasome pathway (29) . Treating GFP-u cells with the proteasome inhibitor, MG132, increases the number of GFP positive cells (Fig. 2B) . The number of GFP positive cells also increases when wild-type (Fig. 2C) or pathological ( Fig. 2D ) AT3 is co-transfected with GFP-u. Pathological AT3 increases the number of GFP positive cells to a greater extent than wild-type AT3. This observation is supported by western blot analysis showing that both wildtype and pathological AT3 increase the amount of GFP-u and that pathological AT3 increases levels of GFP-u to a greater extent (Fig. 2E ). Both wild-type and pathological AT3 increase the amount of GFP-u in cells treated with MG132 (Fig. 2F) ; this suggests that AT3 may be affecting the ubiquitylation arm of the UPP rather than inhibiting proteasome activity.
AT3 decreases the level of 125 I-lysozyme polyubiquitylation
To determine if AT3 could directly alter ubiquitylation of proteins a standard ubiquitylation assay using 125 I-lysozyme was performed. Both wild-type and pathological AT3 decrease the 7 level of polyubiquitylation of 125 I-lysozyme while MBP has no effect on ubiquitylation (Fig. 3A) .
Lysozyme has six lysines that are potential targets for ubiquitylation; therefore, low molecular weight species of ubiquitylated lysozyme ("short chains") likely represent a composite of mono-, di-and tri-ubiquitylated lysines. Both wild-type and pathological AT3 decrease polyubiquitylated species of lysozyme about 90% compared to controls (Fig. 3B) . The level of low molecular weight ubiquitylated species increases 2-3 fold suggesting that AT3 decreases polyubiquitin chain formation which results in a build -up of lysozyme containing short ubiquitin chains.
The effect of AT3 on ubiquitylation of proteins in reticulocyte lysates fraction II used in the assay and unlabeled lysozyme was determined by performing assays with unlabeled lysozyme and ubiquitylation measured by blotting for ubiquitylated proteins. Both wild-type and pathological AT3 decrease ubiquitylation of protein targets in fraction II lysates; lane1 in Fig. 3C shows control ubiquitylation of these substrates and lanes 5 and 6 show an absence of these ubiquitylated species in the presence of wild-type or pathological AT3. As expected, AT3 also decreases polyubiquitylated unlabeled lysozyme while MBP has not effect. Under conditions used in these assays, neither normal nor pathological AT3 is ubiquitylated (not shown; also note the absence of high molecular weight species in lanes 5 and 6 of Fig. 3C that should be present if AT3 is ubiquitylated).
One potential mechanism to account for AT3 decreasing polyubiquitin chains and increasing accumulation of short chains on lysozyme would be that the UIMs of AT3 bind to the growing ubiquitin chains and block polyubiquitin chain extension. To test this possibility the effect of AT3 with mutations in both UIMs (L229A/L249A) on ubiquitylation of 125 I-lysozyme was 8 determined. Surprisingly, the loss of polyubiquitin chain binding by AT3 does not increase formation of polyubiquitin chains on lysozyme but rather, decreases overall ubiquitylation ( Fig.   4A ,B).
AT3 has properties of a ubiquitin protease
Other potential mechanisms that could account for AT3 decreasing ubiquitylation would be that Arabidopsis homologues) with sequences around the catalytic cysteine, histidine, and aspartate/asparagine of members of the USP and UCH families indicate that AT3 shares sequence homology with both the UCH and USP families (Fig. 6A,B) . Importantly, all 3 amino acids in the active site as well as additional amino acids shown to be involved in catalytic activity (marked by asterisks in with or without mutations in the UIM domain cleave the ubiquitin protease substrate, ubiquitin -AMC (Fig. 7B) . Mutating the predicted active site cysteine blocks its catalytic activity consistent with cysteine-14 being critical for ubiquitin protease activity. Although AT3 does not bind monomeric ubiquitin (Fig. 1C) , if it is an ubiquitin protease it should bind monomeric ubiquitin aldehyde (ubiquitin with its C terminal glycine ending as an aldehyde rather than an acid) at its active site. Under the same conditions that ubiquitin does not bind to AT3, ubiquitin aldehyde binds AT3; however, it does not bind to AT3 with the C14A mutation (Fig. 7C ). Together these data indicate that AT3 has ubiquitin protease activity and that cysteine-14 is required for its activity.
Discussion
Data in the present study are consistent with AT3 functioning in the UPP. AT3 contains a UIM domain that binds polyubiquitylated proteins with a strong preference for binding chains containing 4 or more ubiquitins which is the chain length required for proteasome degradation.
Additional support for AT3 functioning in this pathway is data showing that AT3 has ubiquitin protease properties including the ability to remove polyubiquitin chains from 125 I-lysozyme,
cleave an ubiquitin protease substrate, and bind an active site inhibitor of ubiquitin proteases. It is likely that AT3 functions as an ubiquitin protease; however, it seems unlikely that AT3 will have the same ubiquitin protease functions as USP and UCH families. While there is a small amount of overlap in targets of the USP and UCH families in general these ubiquitin protease families appear to perform very different functions. UCH family members are responsible for cleaving ubiquitin from small peptides and adducts as well as UbCEP52 and 80 (31) . Their primary function appears to be to maintain high levels of free ubiquitin in cells (13, 14) . USP 11 family members have a wide diversity of substrates but generally prefer cleaving monoubiquitin or ubiquitin chains from large proteins. Some USPs can also disassemble free ubiquitin chains not linked to proteins. A primary function of USP family members appears to be editing polyubiquitin chains; some USPs edit a wide range of substrates while others edit only a few substrates (13, 14) . In addition to editing, USPs also help maintain high levels of free ubiquitin.
Based on sequence and initial characterization of AT3 protease activity, it is not possible to define a specific function or target preference. However, some potential functions might be 
Rad23 also binds the proteasome through its ubiquitin -like domain (39) as well as polyubiquitylated proteins through its ubiquitin-associated domain (40). Rad23 inhibits ubiquitylation in vitro and is proposed to be a critical link between NER and proteasome function (41-43). At the present it is not clear if interactions of AT3 with VCP or Rad23 have
functional consequences; however, known functions for VCP and Rad23 in the UPP suggest that these interactions may be relevant for both normal and pathological functions of AT3.
Once a more defined protease function and targets have been identified for AT3 it will be critical to determine if expansion of the polyglutamine stretch alters or modulates this function. Data in the present study show that some properties such as binding polyubiquitin chains and proteins, decreasing polyubiquitylation of 125 I-lysozyme, or cleaving the simple substrate ubiquitin-AMC are the same for wild-type and pathological AT3; whereas, other properties such as increasing cellular levels of short-lived GFP-u and effects on short chain ubiquitylation in both the presence and absence of UIM mutations are differentially affected by wild-type and pathological proteins.
Pathological protein increases cellular levels of GFP-u and decreases short-chain ubiquitylation 13 of 125 I-lysozyme to a greater extent than wild-type AT3. These initial studies raise the possibility that expansion of the polyglutamine domain in pathological AT3 modulates its protease activity and/or the range of its substrates.
A critical question is whether AT3's function in the UPP is linked to disease pathology. While it is possible that pathological AT3 acquires new properties that alter UPP functions and this results in dysfunction and disease, another obvious mechanism that would link the two is that pathological AT3 with its destabilizing polyglutamine domain (22) is exposed to misfolded and denatured proteins being degraded. A statistically small fraction of these encounters could result in stable interactions between pathological AT3 and these misfolded proteins. These tightly associated small aggregates may be degraded by the proteasome or act as a "seed" to create larger aggregates and eventually, inclusions. These larger aggregates/inclusions would sequester various proteins including proteasomes (9-11) and inhibit their function (29) . This could create an insidious "feed forward" process in which continued encounters between pathological AT3
and misfolded denatured proteins coupled with decreased proteasome activity resulting from polyglutamine aggregates would increase the concentration of polyglutamine proteins and therefore the probability that misfolded polyglutamine proteins would aggregate. Over the course of decades this could result in inadequate degradation of many cellular regulators resulting in cellular dysfunction. If AT3 were exposed to denatured/misfolded proteins as part of its normal function then a prediction would be that AT3 might be a component of protein aggregates 
Cell transfection
293T cells were co -transfected with myc-tagged AT3 constructs and GFP-u construct. 48 hours after transfection, cells were either treated for 2 hours with 10 uM of the proteasome inhibitor MG132 or left untreated. Cells were harvested using lysis buffer containing 25 mM Tris -HCl, pH 8.0, 10% glycerol, 150 mM NaCl, 2 mM EDTA, 1% NP40, 1 mM DTT, and protease inhibitor cocktail and processed for western blots.
Ubiquitylation assay
Lysozyme was iodinated with Na 125 I using IodoBeads (Pierce) to a specific activity of 0.25 mCi/mg protein. 
Ubiquitin protease assays
Ubiquitin -AMC protease activity . The protease activity of AT3 was measured using the fluorogenic substrate ubiquitin-AMC (Boston Biochem). In short, 100 ul of assay buffer (50 mM HEPES, 0.5 mM EDTA, pH 7.5 containing 0.1 mg/ml ovalbumin and 1 mM DTT) was maintained at 37 °C in the presence of 100 nM MBP-AT3 for 30 minutes. The reaction was initiated by adding ubiquitin -AMC to a final concentration of 0.5 uM and the amount of fluorescence measured at 2.5 min intervals for 15 min using a Biotek Synergy HT fluorimeter. 
